Skip to main content
SpringerLink
Log in
Book cover

Formulation, Characterization, and Stability of Protein Drugs: Case Histories pp 275–301Cite as

Interferon-β-1b (Betaseron®): A Model for Hydrophobic Therapeutic Proteins

  • Chapter

Part of the book series: Pharmaceutical Biotechnology ((PBIO,volume 9))

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Acharya, A. S., Manjula, B. N., and Drummond, R. J., 1985, Conformational analysis of human fibroblast interferon cloned and expressed in E. coli poster presented at FASEB Meeting, Anaheim, CA.

    Google Scholar 

  • Arabje, Y. M., Bittner, G., Yingling, J. M., Storer, B., and Schiller, J. H., 1993, Antiproliferative effects of interferons-α and-β in combination with 5-fluorouracil, cisplatin and cis-and trans-retinoic acid in three human lung carcinoma cell lines, J. Interferon Res. 13:25–32.

    Article  Google Scholar 

  • Ash, M., and Ash, I. 1993, Handbook of Industrial Surfactants, Gower, Hants, UK.

    Google Scholar 

  • Ben-Bassat, A., Bauer, K., Chang, S.-Y., Myabo, K., Boosman, A., and Chang, S., 1987, Processing of the initiation methionine from proteins: Properties of the Escherichia coli methionine aminopeptidase and its gene structure, J. Bacteriol. 169:751–757.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Betaseron, 1995, Physician Desk Reference, pp. 622–626.

    Google Scholar 

  • Borden, E. C., Hawkins, M. J., Sielaff, K. M., Storer, B. M., Schiesel, J. D., and Smalley, R. V., 1988, Clinical and biological effects of recombinant interferon-β administered intravenously daily in phase I trial, J. Interferon Res. 8:357–366.

    Article  CAS  PubMed  Google Scholar 

  • Borden, E. C., Kim, K., Ryan, L., Blum, R. H., Shiraki, M., Tormey, D. C., Comis, R. L., Hahn, R. G., and Parkinson, D. R., 1992, Phase II trials of interferons-α and-β in advanced sarcomas, J. Interferon Res. 12:455–458.

    Article  CAS  PubMed  Google Scholar 

  • Borukhov, S. I., and Strongin, A. Y., 1990, The intrinsic fluorescence of the recombinant human leukocyte interferon-αA and fibroblast-α1, Biochem. Biophys. Res. Comm. 169:282–288.

    Article  CAS  PubMed  Google Scholar 

  • Boublik, M., Moschera, J. A., Wei, C., and Kung, H., 1990, Conformation and activity of recombinant human fibroblast interferon-β, J. Interferon Res. 10:213–219.

    Article  CAS  PubMed  Google Scholar 

  • Chiang, J., Gloff, C. A., Soike, K. F., and Williams, G., 1993, Pharmacokinetics and antiviral activity of recombinant human IFN-β ser17 in African green monkeys, J. Interferon Res. 13:111–120.

    Article  CAS  PubMed  Google Scholar 

  • Colby, C. B., Geigert, J. H., Ruzicka, F. J., Schiller, J. H., Willson, J. K. V., Chen, B. P., Sondel, P. M., and Borden, E. C., 1986, In vitro biological assessment of an interferon beta with a site specific amino acid substitution, in: The Biology of the Interferon System (W. E. Stewert II and H. Schellekens, eds.), Elsevier, pp. 273–278.

    Google Scholar 

  • Day, C., Schwartz, B., Li, B.-L., and Pestka, S., 1992, Engineered disulfide bond greatly increases specific activity of recombinant murine interferon-β, J. Interferon Res. 12:139–143.

    Article  CAS  PubMed  Google Scholar 

  • Derynick, R., Remaut, E., Saman, E., Stranssens, P., De Clercq, E., Content, J., and Fiers, W., 1980, Expression of human fibroblast interferon gene in Escherichia coli, Nature (London) 287:193–197.

    Article  Google Scholar 

  • Dianzani, F., and Dolei, A., 1984, From Isaacs to Escherichia coli, in: Contributions to Oncology (L. Borecky and V. Lackovic, eds.), Karger, Basel, pp. 1–14.

    Google Scholar 

  • Eppstein, D.A., and Schryver, B.B., 1990, Controlled release of macromolecular polypeptides, U.S. Patent No. 4,962,091.

    Google Scholar 

  • Eppstein, D. A., Van Der Pas, M. A., Gloff, C. A., and Soike, K. F., 1989, Liposomal interferon-β: sustained release treatment of simian varicella virus infection in monkeys, J, Infect. Dis. 159:616–620.

    Article  CAS  Google Scholar 

  • Faltynek, C. R., and Baglioni, C., 1984, Interferon is a polypeptide hormone, Microbiol. Sci. 1:81–85.

    CAS  PubMed  Google Scholar 

  • Felgner, P. L., and Eppstein, D. A., 1985, Stable liposomes with aqueous-soluble medicaments and methods for their preparation. European Patent Publication No. 0172007A2.

    Google Scholar 

  • Fernandes, P. M., and Taforo, T., 1991, Formulations for lipophilic IL-2 proteins, U.S.Patent, No. 4,992,271.

    Google Scholar 

  • Fertsch, D., Schoenberg, D. R., German, R. N., Tou, J. Y. L., and Vogel, S. N., 1987, Induction of macrophagela antigen expression by rIFNΓ and down-regulation by IFNα/β and dexamethasone are mediated by changes in steady-state levels of 1a mRNA, J. Immunol. 139:244–249.

    CAS  PubMed  Google Scholar 

  • Geigert, J., Panschar, B. M., Fong, S., Huston, H., Wong, D. A., Wong, D. Y, Taforo, C., and Pemberton, M., 1988, The long-term stability of recombinant (serine-17) human interferon-β, J. Interferon Res. 8:539–547.

    Article  CAS  PubMed  Google Scholar 

  • Geigert, J., Ziegler, D. L., Panschar, B. M., Creasey, A. A., and Vitt, C. R., 1987, Potency stability of recombinant (serine-17) human interferon-β, J. Interfenm Res. 7:203–211.

    Article  CAS  Google Scholar 

  • Grossberg, S. E., Taylor, J. L., Seibenlist, R. E., and Jameson, P., 1985, Biological and immunological assays of human interferons, in: Manual of Clinical Immunology (N. R. Rose, H. Friedman, and J. L. Fahey, eds.), American Society of Microbiology, pp. 295–299.

    Google Scholar 

  • Hershenson, S., Stewart, T, Carrol, C., and Shaked, Z., 1989, Formulation of recombinant interferon-β using laureth-12, a novel nonionic surfactant, in: Therapeutic Peptides and Proteins: Formulation, Delivery and Targeting (D. Marshak and D. Liu, eds.), Cold Spring Harbor, NY, pp. 31–36.

    Google Scholar 

  • Hershenson, S., and Thomson, J., 1989, Isoelectric focusing of recombinant interferon-β, Appl. Theor. Electrophor. 1:123–125.

    CAS  PubMed  Google Scholar 

  • Higgins, P. G., Al-Nakib, W., Willman, J., and Tyrell, D. A. J., 1986, Interferon-βser as prophylaxis against experimental rhinovirus infection in volunteers, J. Interferon Res. 6:153–159.

    Article  CAS  PubMed  Google Scholar 

  • IFNβ Multiple Sclerosis Study Group, 1993, Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial, Neurology 43:655–661.

    Article  Google Scholar 

  • Jacobs, L., O’Malley, J. Freeman, A., and Ekes, R., 1981, Intrathecal interferon reduces exacerbations of multiple sclerosis, Science 214:1026–1028.

    Article  CAS  PubMed  Google Scholar 

  • Jacobs, L., Salazar, A. M.. Herndon, R., et al.. 1987, Intrathecally administered natural human fibroblast interferon reduces exacerbations of multiple sclerosis: results of a multicenter, double-blinded study, Arch. Neurol. 44:589–595.

    Article  CAS  PubMed  Google Scholar 

  • Jameson, P., Grieff, D., and Grossberg, S. E., 1979, Thermal stability of freeze-dried mammalian interferons. Analysis of freeze-drying conditions and accelerated storage tests for murine interferon, Cryobiology 16:301–314.

    Article  CAS  PubMed  Google Scholar 

  • Katre, N., and Knauf, M. J., 1990, Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation, U.S. Patent No. 4,917,888.

    Google Scholar 

  • Kerr, I. M., and Stark, G. R., 1992, The antiviral effects of the interferons and their inhibition, J. Interferon Res. 12:237–240.

    Article  CAS  PubMed  Google Scholar 

  • Kirchner, H., 1986, The interferon system as an integral part of the defense system against infections, Antiviral Res. 6:1–17.

    Article  CAS  PubMed  Google Scholar 

  • Knauf, M. J., Bell, D. P., Hirtzer, P., Luo, Z. P., Young, J. D., and Katre, N. V., 1988, Relationship of effective molecular size on systemic clearance in rats of recombinant interleukin-2 chemically modified with water soluble polymers, J. Biol. Chem. 263:1564–1570.

    Google Scholar 

  • Knobler, R. L., Greenstein, J. I., Johnson, K. P., et al., 1993, Systemic recombinant human interferon-(3 treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up, J. Interferon Res. 13:333–340.

    Article  CAS  PubMed  Google Scholar 

  • Lehrer, S. S., and Leavis, P. C., 1978, Solute quenching of protein fluorescence, in: Methods in Enzymology. Vol. 49, Academic, New York, pp. 222–254.

    Google Scholar 

  • Lin, L. S., Yamamoto, R., and Drummond, R. J., 1986, Purification of recombinant human interferon-β expressed in Escherichia coli, in: Methods in Enzymology, Vol. 119, Academic, New York, pp. 183–192.

    Google Scholar 

  • Mark, D. F., Lu, S. D., Creasey, A. A., Yamamoto, R., and Lin, L. S., 1984, Site-specific mutagenesis of the human fibroblast interferon gene, Proc. Natl. Acad. Sci. USA 81:5662–5666.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mossman, T, 1983, Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxic assays, J. Immunol. Methods 65:55–63.

    Article  Google Scholar 

  • Murray, H. W., 1992. The interferons: macrophage activation, and host defence against nonviral pathogens, J. Interferon Res. 12:319–322.

    Article  CAS  PubMed  Google Scholar 

  • Neighbor, P. A., and Bloom, B. R., 1979, Absence of viral-induced lymphocyte suppression and interferon production in multiple sclerosis, Proc. Natl. Acad. Sci. USA 76:476–480.

    Article  Google Scholar 

  • Noronha, A., Toscas, A., and Jensen, M. A., 1990, Interferon beta augments suppressor cell function in multiple sclerosis, Ann. Neurol. 27:207–220.

    Article  CAS  PubMed  Google Scholar 

  • Patty, D. W., Li, D. K. B., et al., 1993, Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial, Neurology 43:662–667.

    Article  Google Scholar 

  • Pestka, S., 1983, The human interferons: from protein purification and sequence to cloning and expression in bacteria: before, between and beyond, Arch. Biochem. Biophys. 221:1–37.

    Article  CAS  PubMed  Google Scholar 

  • Poklar, N., Vesnaver, G., and Lapanje, S. 1994, Denaturation behavior of α-chymutrypsinogen A in urea and alkylurea solutions: fluorescence studies, J. Protein Chem. 13:323–331.

    Article  CAS  PubMed  Google Scholar 

  • Quesada, J.R., Gutterman, J.U., and Hersh, E. M., 1982, Clinical and immunological study of beta interferon by intramuscular route in patients with metastatic breast cancer, J. Interferon Rex. 2:593–599.

    Article  CAS  Google Scholar 

  • Reder, A. T., and Arnason, B. G. W., 1985, Immunology of multiple sclerosis, in: Handbook of Clinical Neurology. Demyelinating Diseases, Vol. 3 (J. C. Koetsier, G. W. Vinken, G. W. Bruyn, and H. L. Klawans, eds.), Elsevier, Amsterdam, pp. 337–395.

    Google Scholar 

  • Reinhart, J., Malspies, L., Young, D., and Neidhart, J., 1986, Phase I/II trial of human recombinant β-interferon serine in patients with renal cell carcinoma, Cancer Rex. 46:5364.

    Google Scholar 

  • Reiter, Z., 1993. Interferon—a major regulator of natural killer cell-mediated cytotoxicity, J. Interferon Res. 13:247–257.

    Article  CAS  PubMed  Google Scholar 

  • Schein, C. H., 1990. Solubility as a function of protein structure and solvent components, Bio/Technology 8:308–315.

    Article  CAS  PubMed  Google Scholar 

  • Schonfeld, A., Nitke, S., Schatner, A., Wallach, D., Crespi, M., Hahn, T., Lavavi, H., Yarden, O., Shoham, J., Doerner, T., and Revel, M., 1984, Intramuscular human interferon-β injections in treatment of condylomata acuminata, Lancet 1038–1042.

    Google Scholar 

  • Shaked, Z., Stewart, T., Hershenson, S., Thomson, J. W., and Thomson, J., 1993, Formulation processes for pharmaceutical compositions of recombinant beta-interferon, U.S. Patent No. 5,183,746.

    Google Scholar 

  • Shepard, H. M., Leung, D., Stebbing, N., and Goddel, D. V., 1981, A single amino acid change in IFN-β1 abolishes its antiviral activity, Nature (London) 294:563–565.

    Article  CAS  Google Scholar 

  • Soike, K. F., Chou, T.-C., Fox, J. J., Watanabe, K. A., and Gloff, C. A., 1990, Inhibition of simian Varicella virus infection of monkeys by l-(2-deoxy-2 fluoro-1-d-arabinofuranosyl)-5-ethyl uracil (FEAU) and synergistic effects of combination with human recombinant interferon-β, Antiviral Res. 13:165.

    Article  CAS  PubMed  Google Scholar 

  • Soike, K. F., Eppstein, D., Gloff, C. A., Cantrell, C., Chou, T.-C., and Gerone, P. J., 1987, Effect of 9-(l,3-dihydroxy-2-propoxymethyl)guanine and recombinant human interferon alone and in combination on Simian Varicella virus infection in monkeys, J. Infect. Dis. 156:607–614.

    Article  CAS  PubMed  Google Scholar 

  • Utsumi, J., Yamazaki, S., Hosoi, K., Kimura, S., Hanada, K., Shimazu, T., and Shimizu, T, 1987, Characterization of E. coli-derived recombinant human interferon-β as compared with fibroblast human interferon-β, J. Biochem. 101:1199–1208.

    Article  CAS  PubMed  Google Scholar 

  • Utsumi, J., Yamazaki, S., Kawagucki, K., Kimura, S., and Shimizu, H., 1989, Stability of human interferon-β1: oligomeric human interferon-β1 is inactive but is reactivated by monomerization, Biochim. Biophys. Acta 998:167–172.

    Article  CAS  PubMed  Google Scholar 

  • Utsumi, J., Yamazaki, S., Hosoi, K., Shimizu, H., Kawaguchi, K., and Inagaki, F., 1986, Conformations of fibroblast and E. coli-derived recombinant human interferon-βs as studied by nuclear magnetic resonance and circular dichroism, J. Biochem. 99:1533–1535.

    Article  CAS  PubMed  Google Scholar 

  • Vincent, M., Sierra, I. M., Berbaron-Santos, M. N., Diaz, A., Diaz, M., Padron, G., and Gallay, J. 1992, Time-resolved fluorescence study of human recombinant interferon α2 association state of the protein, spatial proximity of the two tryptophan residues, Eur. J. Biochem. 210:953–961.

    Article  CAS  PubMed  Google Scholar 

  • Wetzel, R., Johnson, P. D., and Czarniecki, C. W., 1983, Roles of the disulphide bonds in a human alpha interferon, in: The Biology of the Interferon System (E. De Maeyer and H. Schellekens, eds.), Elsevier, Amsterdam, pp. 101–120.

    Google Scholar 

  • Zoon, K., 1987, Human interferons: structure and function, in: Interferon 9 (I. Gresser, ed.), Academic, New York, pp. 1–13.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Analytical Development, Chiron Corporation, Emeryville, California, 94608, USA

    Leo S. Lin & Michael G. Kunitani

  2. Department of Formulation Development, Chiron Corporation, Emeryville, California, 94608, USA

    Maninder S. Hora

Authors
  1. Leo S. Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael G. Kunitani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maninder S. Hora
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Megabios Corporation, Burlingame, California, USA

    Rodney Pearlman

  2. Scios Nova, Inc., Mountain View, California, USA

    Y. John Wang

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Kluwer Academic Publishers

About this chapter

Cite this chapter

Lin, L.S., Kunitani, M.G., Hora, M.S. (2002). Interferon-β-1b (Betaseron®): A Model for Hydrophobic Therapeutic Proteins. In: Pearlman, R., Wang, Y.J. (eds) Formulation, Characterization, and Stability of Protein Drugs: Case Histories. Pharmaceutical Biotechnology, vol 9. Springer, Boston, MA. https://doi.org/10.1007/0-306-47452-2_6

Download citation

  • DOI: https://doi.org/10.1007/0-306-47452-2_6

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-306-45332-8

  • Online ISBN: 978-0-306-47452-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation